iPS Cells & Regenerative Medicine– category –
-
iPS Cells & Regenerative Medicine Weekly Report June 28, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report June 28, 2026 (PDF) — Download Weekly Report June 28, 2026 (PDF) — DownloadDownload 🎙 Podcast June 28, 2026 (... -
Europe’s Regulatory Frontier for Advanced Biologics: Real-World Evidence and Patient Voices Shape Cell and Gene Therapies
ResearchGate (論文) Global Overview A new ResearchGate paper explores Europe's progressive regulatory landscape for advanced cell and gene therapies, a class of complex, engineered biologics. It underscores the critical role of integrati... -
Samsung Biologics Expands Bio R&D Center Beyond CDMO Support, Investing in Next-Gen Modalities, AI, and Machine Learning
Korea Biomedical Review (KBR) South Korea Overview Samsung Biologics is significantly expanding its Bio R&D Center beyond traditional Contract Development and Manufacturing Organization (CDMO) support. The company is focusing on thre... -
Long-Read DNA Sequencers Market to Accelerate by 2035 Amid Biopharma Quality Control Demand: Essential for CAR-T Genomic Evaluation
IndexBox News and Statistics Global Overview The long-read DNA sequencer market is projected for accelerated growth by 2035, driven by biopharmaceutical quality control demands, particularly the need for high-resolution genomic evaluatio... -
Top 10 Emerging Healthcare Technologies in 2026: CRISPR Gene Editing Established as Therapeutic Category, Regenerative Medicine Nearing Clinical Application
Slate USA Overview An article on 10 emerging healthcare technologies to watch in 2026 highlights that CRISPR gene editing is moving beyond the lab to become a bona fide therapeutic category. Additionally, regenerative medicine and stem c... -
Advances in Multiple Myeloma Treatment: CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates Evolving in Approved & Clinical Stages
Myeloma Crowd USA Overview An article summarizing the latest advancements in multiple myeloma treatment highlights the diversification of approved and investigational approaches, including CAR-T cell therapies, bispecific T-cell engagers... -
ROKIT America Clears SEC Registration Statement for Nasdaq Listing, Raises KRW 38 Billion to Accelerate Regenerative Medicine Commercialization
Korea Biomedical Review (KBR) South Korea Overview ROKIT America has secured U.S. SEC registration statement approval for its Nasdaq listing, aiming to expand its regenerative medicine clinical programs and commercial activities across N... -
Synthetic Biology Firm Syntax Bio Expands Series A to $14.4M, Boosting Preclinical Research for CRISPR-Based Type 1 Diabetes Beta-Cell Therapy
Fierce Biotech USA Overview Synthetic biology company Syntax Bio announced an expansion of its Series A funding round to $14.4 million, pushing total capital raised over $25 million. This capital injection will primarily drive the develo... -
Regentis Biomaterials Secures $6.5M Private Placement to Accelerate Regenerative Tissue Repair Solutions
BioSpace (Press Release) イスラエル Overview Regentis Biomaterials, an innovator in regenerative medicine, has successfully closed a $6.5 million private placement, securing capital through the issuance of common shares and warrants. Thi... -
Dermatology & Plastic Surgery Specialists Introduces Exosome Therapy for Anti-Aging: Harnessing Stem Cell Culture-Derived Extracellular Vesicles for Skin Regeneration
Dermatology & Plastic Surgery Specialists (Blog) USA Overview Dermatology & Plastic Surgery Specialists has introduced exosome therapy as an anti-aging treatment. This therapy utilizes extracellular vesicles to signal skin cells for ...
